Dihexa vs Selank
Comparison of Dihexa (Very Low evidence) and Selank (Moderate evidence).
Last updated: February 12, 2026
Dihexa
Selank
Overview
Dihexa and Selank are both studied in the peptide research space.
Dihexa: An angiotensin IV analog developed by Washington State University researchers, claimed to enhance cognition through HGF/c-Met signaling.
Selank: A synthetic heptapeptide derived from the immunomodulatory peptide tuftsin, developed by Russian researchers and approved in Russia since 2009 for anxiety and neurasthenia.
Evidence Comparison
| Aspect | Dihexa | Selank |
|---|---|---|
| Evidence Level | Very Low | Moderate |
| Human Studies | 0 | 5 |
| Preclinical Studies | 12 | 20 |
| Total Sources | 12 | 25 |
Key Differences
| Aspect | Dihexa | Selank |
|---|---|---|
| Category | Cognitive | Cognitive |
| Evidence Strength | Very Low | Moderate |
| Total Sources | 12 | 25 |
| Human Studies | 0 | 5 |
Summary
- Dihexa: Very Low evidence with 12 total sources (0 human)
- Selank: Moderate evidence with 25 total sources (5 human)
This comparison is for educational purposes only and is not medical advice. Consult a healthcare professional before making any decisions about peptide use.
View Full Dossiers
Stay Updated on Peptide Comparisons
Get notified when we publish new comparison dossiers and evidence reviews.
No spam. Unsubscribe anytime.
Disclaimer: This comparison is for educational purposes only and does not constitute medical advice. Individual responses to medications vary. Always consult a qualified healthcare provider before making treatment decisions.